Melasma is one of the most frustrating pigment problems clinics treat. It comes back after laser, it flares with sun and hormones, and it often fails to respond to hydroquinone alone. That is why tranexamic acid injection for skin whitening and melasma control has moved from a niche technique to a standard request in aesthetic practices across Asia, the Middle East and Europe. This guide covers how tranexamic acid (TXA) works on pigment, what the published clinical data actually show, how practitioners typically run a TXA mesotherapy protocol, and what distributors and clinic brands should check before sourcing a TXA formula.
What Is Tranexamic Acid and Why Is It Used on Skin?
Tranexamic acid is a synthetic derivative of the amino acid lysine. It was first developed as an antifibrinolytic drug, meaning it reduces bleeding by blocking the conversion of plasminogen to plasmin. Dermatologists became interested in it after researchers observed that blocking the plasminogen–plasmin pathway also reduced ultraviolet-induced pigmentation.
In aesthetic medicine, TXA is now used in three main forms:
Topical serums and creams, usually at low concentrations
Oral tablets, prescribed by physicians for resistant melasma
Intradermal microinjection (mesotherapy), where a dilute solution is placed directly into the pigmented area
This article focuses on the third route, often searched as "tranexamic acid mesotherapy" or "tranexamic acid ampoule for skin". For a broader overview of injectable brightening options, see our guide on how skin brightening injectables help treat hyperpigmentation.
How Tranexamic Acid Reduces Pigmentation
Melasma is not just "too much melanin". It involves a conversation between several cell types in the skin. Here is the simplified version of how TXA interrupts it.
Blocking the plasmin signal
When skin is exposed to UV light, keratinocytes produce more plasminogen activator. Plasmin then releases signaling molecules such as arachidonic acid and prostaglandins, which push melanocytes to produce more melanin. TXA blocks plasminogen activation, so that stimulating signal is weakened at its source.
Targeting the vascular component
Melasma lesions often show more small blood vessels than surrounding skin, and vascular growth factors appear to feed the pigment cycle. Because TXA also acts on the plasmin pathway involved in angiogenesis, it may help with the reddish-brown, vascular look of some melasma patches. This is one reason TXA behaves differently from pure tyrosinase inhibitors.
Why this matters for treatment choice
Ingredients such as glutathione, vitamin C, kojic acid and arbutin mostly act on melanin synthesis itself. TXA acts upstream, on the signals that trigger it. That makes it a logical partner rather than a replacement. If you want the detail on the antioxidant side, our article on glutathione and skin whitening injections explains how glutathione influences pigment. The rest of this guide stays with TXA and melasma.
What the Clinical Evidence Shows
TXA microinjection has been studied in peer-reviewed trials, though most are small and open-label. Two frequently cited studies give a realistic picture:
Lee et al., Dermatologic Surgery (2006). In a 12-week open pilot study of 100 Korean women with melasma, 0.05 mL of TXA (4 mg/mL) was injected intradermally at 1 cm intervals once a week. Eighty-five patients completed the study. The mean Melasma Area and Severity Index (MASI) fell from 13.22 at baseline to 7.57 at week 12, and side effects were described as minimal.
Budamakuntla et al., Journal of Cutaneous and Aesthetic Surgery (2013). Sixty patients were randomized to TXA microinjections or TXA delivered with microneedling, with three monthly sessions. MASI improved by 35.72% in the microinjection group and 44.41% in the microneedling group, with no major adverse events reported.
What these studies suggest:
TXA mesotherapy can produce a meaningful reduction in melasma severity over 8–12 weeks.
Results vary. In the Lee study, most patients rated their improvement as "fair" (26–50% lightening) rather than complete clearance.
Delivery method matters, and combination with microneedling may improve penetration.
Neither study proves permanent clearance. Melasma is a chronic condition, so clinics should present TXA as a control and maintenance tool, not a cure.
A Typical TXA Mesotherapy Protocol
Protocols differ between practitioners and products, and any treatment plan should follow the product's instructions for use and local medical regulations. The general structure used in clinics looks like this.
Patient selection and preparation
Confirm the diagnosis. Melasma, post-inflammatory hyperpigmentation and solar lentigines respond differently.
Screen for contraindications. TXA affects clotting pathways, so a history of thromboembolism, clotting disorders, anticoagulant therapy or pregnancy calls for physician review before treatment.
Photograph the area under consistent lighting, and score it with MASI or a similar scale for objective follow-up.
Cleanse the skin and apply topical anesthetic if needed.
Injection technique
Depth: superficial intradermal placement, roughly 0.5–1 mm.
Spacing and volume: small aliquots spread evenly across the lesion. Published protocols used about 0.05 mL per point at 1 cm intervals.
Delivery tools: insulin syringe, meso gun, or microneedling pen and roller, depending on product design and clinic preference.
Session frequency
Published studies used weekly sessions (Lee 2006) or monthly sessions (Budamakuntla 2013). Many commercial TXA mesotherapy solutions recommend one session every two weeks. A course usually runs 4–8 sessions, followed by maintenance treatments as needed.
Aftercare
Strict broad-spectrum sun protection every day. Without it, any improvement will fade.
Avoid heat, saunas and strong actives for 24–48 hours.
Expect mild redness, pinpoint bruising or small bumps that usually settle within a day or two.
Combining TXA With Other Brightening Actives
TXA's upstream mechanism pairs well with ingredients that act further down the melanin pathway. Modern formulations often combine TXA with:
Glutathione and vitamin C for antioxidant support and tyrosinase inhibition
Kojic acid, arbutin or glycolic acid to support even tone and cell turnover
PDRN (polydeoxyribonucleotide) to support skin repair and barrier recovery, which matters for sensitive or laser-damaged melasma skin
Intradermal TXA has a favorable safety record in the published studies, but responsible use still depends on the product and the practitioner.
Sterility and pyrogen control are non-negotiable for any injectable. Poorly made products are a bigger real-world risk than the active ingredient itself.
Local reactions such as erythema, burning, bruising and transient swelling are the most commonly reported side effects.
Systemic risk is mainly discussed for oral TXA, which reaches much higher blood levels. Screening for clotting risk is still good practice before injection.
Regulatory status varies by country. In many markets, TXA mesotherapy solutions are sold as cosmetic or medical-device products rather than as drugs. Clinics should check local rules before use.
Sourcing TXA Mesotherapy Solutions: A Checklist for Distributors and Clinic Brands
Demand for TXA products is strong in markets with high rates of melasma, including Southeast Asia, the Middle East, Latin America and parts of Europe. If you plan to import or private-label a TXA formula, check:
Formula transparency: a full ingredient list with stated concentrations, not just "TXA complex".
Manufacturing standards: ISO 13485 and GMP-compliant production, with batch records.
Documentation: a certificate of analysis (COA), sterility and endotoxin test reports, and stability and shelf-life data for every batch.
Packaging options: vial size, box quantity and labeling that meet your target market's registration requirements.
Customization: whether the manufacturer can adjust the active blend, for example TXA with PDRN versus TXA with glutathione, for your positioning.
AOMA supports distributors and clinic brands with formulation, filling and private-label packaging. Learn more about our custom mesotherapy OEM solutions.
FAQ
Is tranexamic acid injection effective for skin whitening?
TXA is best described as a pigment-control ingredient rather than a "whitening" agent. Clinical studies show it can reduce melasma severity and even out tone, but it does not change a person's natural skin color.
How many TXA mesotherapy sessions are needed for melasma?
Most courses involve 4–8 sessions spaced one to four weeks apart, depending on the protocol and product. Visible improvement in published studies appeared at around 8–12 weeks.
Is TXA mesotherapy better than oral tranexamic acid?
They serve different purposes. Oral TXA is a prescription medicine with systemic effects and needs physician oversight. Intradermal TXA delivers a small local dose directly to the lesion. A dermatologist may combine both for resistant cases.
Can melasma come back after TXA treatment?
Yes. Melasma is chronic and is triggered by UV light, heat and hormones. Daily sun protection and periodic maintenance sessions are needed to keep results.
Can TXA be combined with laser or peels?
Many practitioners use TXA alongside gentle peels or low-energy lasers. Treatments should be spaced appropriately and planned by a qualified professional to avoid irritation and rebound pigmentation.
References: Lee JH, Park JG, Lim SH, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32(5):626–631. Budamakuntla L, Loganathan E, Suresh DH, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6(3):139–143.
This article is for professional information only and is not medical advice. Treatments should be performed by qualified practitioners in line with local regulations.
Dr. Emily Carter (MD, Fellow of the American Academy of Dermatology) is a board-certified cosmetic surgeon in New York City with over 9 years of specialized experience in hyaluronic acid fillers, acne scar treatment, and minimally invasive facial contouring. She is particularly recognized for her expertise in advanced injectable therapies that effectively lighten acne scars, promote skin healing, and restore smoothness through targeted skin repair injection and skin booster techniques.
